Skandinaviska Enskilda Banken Ab (Publ) Crinetics Pharmaceuticals, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $24.3 Billion
- Q3 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 178,584 shares of CRNX stock, worth $7.14 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
178,584
Previous 18,117
885.73%
Holding current value
$7.14 Million
Previous $521,000
1327.64%
% of portfolio
0.03%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
240Shares Held
91.3MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.17MShares$367 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$256 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$249 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$232 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$224 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.15B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...